Epothilone D Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

491.68

DMSO: 300mg/mL (610.15mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

C27H41NO5S

CC1CCCC(=CCC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC2=CSC(=N2)C)C)C

189453-10-9

To evaluate whether Epothilone D improves MT and axonal function in PS19 mice, groups of 3-month old male PS19 mice received weekly i.p. injections of vehicle or Epothilone D (1mg/kg or 3mg/kg) for a total of 3 months. In addition, 3-month old non-Tg littermates received 3mg/kg Epothilone D or vehicle. The 3mg/kg Epothilone D dose corresponds to ~10-fold less than that used in Phase II clinical study, which should minimize side-effects such as neutropenia that are observed with MT-stabilizing drugs in human subjects. PS19 and WT mice that receive Epothilone D show no signs of drug intolerance. Indeed, all drug-treated mice exhibited weight gain that is indistinguishable from vehicle-treated animals. Likewise, relative organ weights are similar in vehicle- and Epothilone D-treated mice. The motor performance of Epothilone D-treated mice, assessed using a standard rotarod test, is not significantly different from vehicle-treated cohorts [2].

Cytoskeletal Signaling; Microtubule Associated